Aesthetic Medicine Symposium - November 14-16 in Scottsdale, AZ!Secure Your Spot
Celebrating 20 Years of Excellence in Botox®, Aesthetic Medicine & Medical Weight Management Training & Certification
Aesthetic Medicine Symposium — Nov 14–16, Scottsdale, AZ Secure Your Spot →
Empowering Medical Aesthetic Clinics, Practitioners, and Patients
Headache After Botox®
Last updated: September 2026
A headache after Botox® is one of the most frequently reported reactions to treatment — and one of the most frequently misdescribed. Many patient-facing pages call it “rare.” The FDA prescribing information does not. In the forehead-line trials that supported approval, headache occurred in 9% of treated patients compared with 5% on placebo, and the label names it the most common adverse reaction for that indication.
That gap matters for consent. A patient who was told a headache would be unusual, and then gets one, assumes something went wrong. A patient who was told it happens to roughly one in ten people, usually settles quickly, and is more likely the first time around, reads the same symptom as expected. The difference is entirely in what the injector said beforehand — which is why injection technique and facial anatomy are only half of a good treatment; the consultation is the other half.
This guide sets out what the labels and the published evidence actually show about headache after Botox®: how often it happens across the six botulinum toxin products sold in the United States, when it tends to start, what it typically feels like, what the data say about first-time patients, and the specific circumstances in which a post-treatment headache needs to be assessed rather than waited out.
Key Takeaways
Headache is common, not rare. 9% versus 5% on placebo in the BOTOX® Cosmetic forehead-line trials, where the label names it the most common adverse reaction.
Its absence from the frown-line table is a reporting threshold, not evidence of rarity. Those tables only print reactions that exceed roughly 1% and beat placebo.
First-time patients are affected far more often. A 2026 prospective study found headache in 45.5% of first-time recipients versus 8.8% of repeat patients.
Onset is usually early; duration is genuinely unknown. The one cohort that measured onset found 75% within 24 hours. No study published between 2020 and 2026 reports a mean duration.
Migraine patients need a specific warning. Severe worsening of migraine requiring hospitalization occurred in about 1% of Botox®-treated patients in the chronic migraine trials, usually in the first week.
Jaw treatment is off-label in the US. Neither TMJ disorder nor bruxism is an approved indication, and no neurotoxin is yet approved for masseter prominence.
Can Botox® Cause Headaches?
Yes — and more often than most patient education material suggests. Botox® is widely used to treat headache, which creates an intuitive but mistaken assumption that it cannot also cause one. Both are true at the same time: the same molecule that prevents chronic migraine over months can produce a short-lived headache in the days right after an injection.
The clearest figure comes from the BOTOX® Cosmetic prescribing information revised in October 2024. In the forehead-line trials, headache was reported by 58 of 665 treated patients (9%) against 17 of 315 placebo patients (5%). The label's Highlights section lists it explicitly as one of the two most common adverse reactions for that indication, alongside brow ptosis at 2%.
9%Forehead-line trials (vs 5% placebo)
6.3%Pooled across 24 RCTs (vs 4% placebo)
12.7%Real-world cosmetic cohort, 2026
~1%Severe migraine worsening, CM trials
Why the frown-line table doesn’t list headache
A reasonable objection: headache does not appear in the glabellar (frown line) or lateral canthal (crow’s feet) adverse reaction tables at all. That is a feature of how labels are built, not a finding. Those tables print only reactions that cleared a reporting threshold — broadly, above 1% and more frequent than placebo. A reaction that fell below the line is simply not printed. “Not listed” is not the same as “does not occur,” and reading it that way is how “rare” found its way onto so many pages.
Headache rates across the six US botulinum toxin products
Every type A toxin approved in the United States reports headache in its label, and in four of the six it is named the most common adverse reaction. The spread below looks dramatic and mostly is not — see the caveat under the table before quoting any of it comparatively.
Product
Headache, treated
Placebo
Label notes
Label revised
BOTOX® Cosmetic — forehead lines
9% (58/665)
5% (17/315)
Named most common adverse reaction for this indication
10/2024
BOTOX® Cosmetic — glabellar & crow’s feet
Not listed
—
Below the table’s reporting threshold
10/2024
Dysport®
9%
5%
Listed among reactions ≥2%, not singled out
9/2023
Xeomin®
5%
2%
7% and most common on repeat open-label dosing
6/2026
Jeuveau®
12% (57/492)
13% (21/162)
Named most common — but lower than placebo
4/2023
Daxxify®
6% (26/406)
2% (4/203)
Named most common adverse reaction
11/2023
Letybo®
2% (17/911)
1% (2/310)
Named most common; bundles migraine and procedural headache
11/2024
Glabellar-line trials unless noted. These are not head-to-head comparisons: denominators, reporting thresholds, follow-up windows and the way related events are grouped all differ between labels, so the 2–12% spread is substantially a labelling artifact rather than a demonstrated difference in potency or tolerability.
The most useful number for consent is the placebo column. Across these labels, placebo headache rates run from 1% to 13% — and in the Jeuveau® trials the placebo arm reported more headache than the treated arm. Headache is common in the general population, common after any needle procedure, and common in people anticipating a cosmetic result. A meaningful share of “Botox® headaches” would have happened anyway.
Headaches from Botox®
A headache after Botox® treatment is most common in the initial days following the injections. Several explanations are routinely offered — the body’s response to the injections themselves, temporary muscle stiffness, or adjustment to altered muscle function — and it is worth being candid that these are reasonable hypotheses rather than established mechanisms. No mechanistic study has confirmed any of them.
The two clinical datasets that have looked at the question point in different directions. A 2024 retrospective cohort of 70 patients treated for blepharospasm and hemifacial spasm found a statistically significant link between how much pain a patient felt during the injection and whether they developed a headache afterwards — which supports a straightforward needle-and-periosteum trauma explanation. A 2026 prospective study of 102 cosmetic patients found no such association, and no relationship with dose either, but did find a strong first-treatment effect. The honest summary is that both procedural trauma and adaptation to the toxin’s muscular effect are plausible, and the evidence cannot currently separate them.
The first-treatment effect
The single most actionable finding in the recent literature is how sharply headache risk drops after a patient’s first session.
Headache incidence by treatment history (prospective cosmetic cohort, n=102)
First-time patients45.5%
Previously treated8.8%
Whole cohort12.7%
Akpınar et al., Journal of Cosmetic Dermatology, 2026. Bars are scaled to a 50% axis. The difference between first-time and repeat patients was statistically significant (p=0.005). Single-centre, one toxin brand, no control group — a strong signal, not a settled figure.
For a practitioner, this converts directly into a consent line: new patients should be told that a mild headache in the first days is common and usually does not recur at their next appointment. It also reframes a complaint that would otherwise read as a technique failure — a first-timer’s headache is, on this evidence, close to expected.
How Long Does a Botox® Headache Last?
This is the question patients actually search, and it deserves an honest answer rather than a confident one. No study published between 2020 and 2026 reports a mean or median duration for post-injection headache. The literature describes it only as short-lived, transient and self-limited. Any page quoting a precise window — “24 to 48 hours,” “two to four days” — is not citing published data.
What can be said with reference to evidence is when it tends to start, and what each stage should prompt.
Time after injection
What the evidence supports
What it should prompt
First 24 hours
The most commonly reported onset window. In the one cohort that measured onset, 75% of headaches began here.
Reassurance. Consistent with injection-site trauma; simple analgesia as appropriate.
Days 1–3
Where most reported cases sit. Described consistently as mild to moderate and self-limiting.
Routine follow-up only. Worth a check-in call for a first-time patient.
Days 3–7
Still within the reported window, though less common. Coincides with the onset of visible muscular effect.
Ask about brow heaviness and eyelid position, which can produce a tension-type ache.
Week 2 onward
Uncommon. Peak muscular effect is reached around this point.
Reassess. Consider compensation patterns and non-Botox® causes.
Beyond a few weeks
Not a typical pattern and not characterised in the literature.
Full evaluation for an alternative cause; do not attribute it to the toxin by default.
Onset figure from Bilgin et al., Clinical Neuropharmacology, 2024 — a retrospective cohort of 70 patients treated for blepharospasm and hemifacial spasm, not a cosmetic population. It is the only quantified onset figure in the 2020–2026 literature and should be treated as low-certainty.
What Does a Botox® Headache Feel Like?
Patients most often describe a dull, tight, pressure-like ache across the forehead, brow or temples — closer to a tension-type headache than to a throbbing, one-sided migraine. Some report point tenderness at the injection sites in the first hours, which fits the procedural-trauma explanation and typically resolves fastest.
The clinically useful part is the pattern that doesn’t fit. Severe pain, pain that is escalating rather than settling, strictly one-sided pain, or headache accompanied by visual change, drooping of the eyelid or brow, or any difficulty swallowing, speaking or breathing, is not the typical post-injection picture. The last of those relates to the boxed warning on distant spread of toxin effect that applies to every botulinum toxin product, and needs urgent assessment rather than reassurance. Eyelid and brow changes are common enough to have their own presentation — see our guide to droopy eyelid after Botox® and ptosis management.
Headache After Botox® Injections in Forehead
The forehead is where headache is best documented, and it is no coincidence: the 9% figure comes specifically from the forehead-line trials, in which patients received 20 units to the frontalis alongside 20 units to the glabellar complex. Treating the frontalis means treating the muscle that lifts the brow, so any over-reduction of its activity can leave the brow sitting lower, the upper lid feeling heavy, and a compensatory ache developing across the forehead and temples.
This is one reason forehead lines are rarely treated in isolation. Weakening the frontalis without addressing the depressors that oppose it is the classic route to brow heaviness, which is why strategic full-face treatment planning matters more here than almost anywhere else on the face. Dose, placement height above the orbital rim, and the patient’s existing brow position all feed into it.
A useful practical note: in the 2026 prospective cohort, every patient who developed a headache had received injections involving the upper face. None occurred after treatment confined to the masseter or the axilla. Whatever the mechanism turns out to be, it appears to be regional rather than systemic.
Headache After Botox® in Jaw
Botulinum toxin is widely used in the jaw — for temporomandibular joint (TMJ) disorder, for bruxism, and for masseter slimming. It is important to be precise about the regulatory position: none of those are FDA-approved indications in the United States. All are off-label use, which is lawful within a practitioner’s scope but should be documented and consented as such.
That picture is currently moving. On August 4, 2026, the FDA accepted Allergan Aesthetics’ supplemental Biologics License Application for BOTOX® Cosmetic in masseter muscle prominence, on the strength of two phase 3 trials (M21-416 and M21-417) that both met their primary endpoints, with p-values of 0.0046 and 0.0014 and no new safety signals reported. If approved, it would be the first neurotoxin indicated for the masseter. Until then, masseter treatment for jawline slimming remains off-label, and training and documentation should reflect that.
On headache specifically, the evidence is more reassuring here than for the upper face. The 2026 prospective study recorded no headaches at all in patients whose injections were confined to the masseter. Patients treated in the jaw do commonly report chewing fatigue and local soreness in the first one to two weeks as masticatory strength reduces, which is a different complaint and should be described separately at consent.
Migraine After Botox®
Botox® has been FDA-approved for the prevention of chronic migraine since 2010, in adults with at least 15 headache days per month lasting four hours or longer. Its efficacy in that population is well established. The label also carries a warning that patient-facing pages almost universally omit.
From the BOTOX® therapeutic prescribing information: severe worsening of migraine requiring hospitalization occurred in approximately 1% of Botox®-treated patients in the two pivotal studies, usually within the first week after treatment, compared with 0.3% of placebo-treated patients.
The same trials reported headache in 5% of treated patients versus 3% on placebo, migraine in 4% versus 3%, and neck pain in 9% versus 3% — the last being the most frequent reaction of all, and a consequence of the cervical injection sites in the chronic migraine protocol.
Describing post-treatment migraine as “typically mild” is therefore not accurate as a blanket statement. For most patients it is; for roughly one in a hundred in the trial population it was severe enough to require admission. Migraine patients should be told explicitly to report a marked worsening in the first week rather than assume it is part of the adjustment.
Prolonged Headache After Botox®
A headache that persists well beyond the first several days is uncommon and is not well characterised in the published literature — which means there is no evidence base for reassuring a patient that it will pass on its own. It should be assessed rather than waited out.
Assessment should cover the obvious alternatives before the toxin is blamed: whether brow or eyelid position has changed in a way that could be driving a tension-type headache; whether the patient has an underlying primary headache disorder that happens to have flared; whether there is a coincidental cause such as infection, dental pathology or medication-overuse headache from treating the first few days aggressively; and whether any red-flag features are present. Where a technique factor does look likely, the usual adjustments for subsequent sessions are dose reduction, a change in placement relative to the orbital rim, or rebalancing treatment across the antagonist muscle groups rather than abandoning treatment altogether.
Reducing the Risk: Practitioner Considerations
Nothing in the evidence base supports a technique that eliminates post-injection headache, and claiming otherwise sets up a complaint. What the data do support is better prediction and better framing.
Set the expectation at consent, not afterwards. Roughly one in ten across the trials, closer to one in two among first-timers in the prospective cohort. A predicted symptom is tolerated; an unpredicted one becomes a complaint.
Flag the first session specifically. The 45.5% versus 8.8% difference is the strongest single predictor in the literature, and it is reassuring news — it usually does not repeat.
Don’t chase dose reduction as a fix. Neither of the two cohorts found an association between dose and headache. Reducing units to avoid headache trades away efficacy for an effect the evidence does not support.
Watch brow position at the two-week review. Brow heaviness is a plausible route to a later tension-type headache, and it is a technique variable you can actually change.
Separate the jaw conversation. Masseter patients report chewing fatigue, not headache. Consent for the off-label indication separately.
Know the escalation triggers cold. Swallowing, speech or breathing difficulty at any point after any botulinum toxin product is a boxed-warning presentation, not a headache question.
Product choice is a reasonable question to expect from patients who have read the label figures, and the honest answer is that these rates cannot be compared directly. If you are fielding that conversation regularly, our breakdown of how Botox®, Dysport®, Xeomin® and the newer toxins differ covers the properties that genuinely do vary between them.
Free Online Botox® Training · Earn 1 CME
Try Botox® training free. Earn 1 CME on us.
Get self-paced access to a real IAPAM Botox® module — watch step-by-step injection technique, follow along with our physician instructors, and claim 1 AMA PRA Category 1 CME when you finish.
Enter your details and we’ll email your access link.
Frequently Asked Questions
Is a headache after Botox® normal?
Yes. Headache is one of the most commonly reported reactions to botulinum toxin injection. In the BOTOX® Cosmetic forehead-line trials it occurred in 9% of treated patients compared with 5% of placebo patients, and the label names it the most common adverse reaction for that indication. A pooled analysis of 24 randomized trials found headache or migraine in 6.3% of botulinum toxin sessions versus 4% of placebo sessions. It is common, usually mild, and self-limited.
How long does a Botox® headache last?
There is no published average. No study between 2020 and 2026 reports a mean or median duration for post-injection headache; the literature describes it only as short-lived and self-limited. The one cohort that measured onset found 75% of headaches began within the first 24 hours. Any source quoting an exact figure such as 24 to 48 hours is not citing published data. A headache that persists beyond a few days, or that is severe, should be evaluated rather than waited out.
What does a Botox® headache feel like?
Patients most often describe a dull, tight, pressure-like ache across the forehead, brow or temples, similar to a tension-type headache rather than a throbbing migraine. Some report tenderness at the injection points in the first hours, which is consistent with needle trauma rather than the toxin itself. Sharp, one-sided, severe or progressively worsening pain is not the typical pattern and warrants assessment.
Why do first-time Botox® patients get more headaches?
A 2026 prospective study of 102 cosmetic patients found headache in 45.5% of first-time recipients compared with 8.8% of patients who had been treated before, a statistically significant difference. The same study found no relationship between headache and toxin dose. The reason is not established; proposed explanations include adaptation to altered muscle function and first-exposure effects. It is a useful point to raise during consent with a new patient.
Can Botox® make migraines worse?
It can, in a small number of patients. Botox® is FDA-approved to prevent chronic migraine, but the therapeutic label reports that severe worsening of migraine requiring hospitalization occurred in approximately 1% of Botox®-treated patients in the pivotal trials, usually within the first week after treatment, compared with 0.3% of placebo patients. The same trials report headache in 5% and migraine in 4% of treated patients. Patients should be told to report severe worsening promptly.
Does Botox® in the jaw or masseter cause headaches?
The available evidence does not support it. In the 2026 prospective cosmetic study, no headaches occurred after masseter-only or axilla-only injection; every case involved the upper face. Note also that treating TMJ disorder or bruxism with botulinum toxin is off-label in the United States. Allergan’s application for a masseter muscle prominence indication was accepted by the FDA on August 4, 2026, but as of this update no neurotoxin is approved for the masseter.
When should a patient call their provider about a headache after Botox®?
Advise contact if the headache is severe, if it lasts beyond a few days, if it is getting worse rather than better, if it is accompanied by drooping of the eyelid or brow, double or blurred vision, or difficulty swallowing, speaking or breathing, or if a migraine patient experiences a marked worsening in the first week. The swallowing and breathing symptoms relate to the boxed warning on distant spread of toxin effect and require urgent assessment.
Headache After Botox® Injection: Conclusion
Headache after Botox® is common rather than rare, usually mild, usually early, and substantially more likely at a patient’s first treatment than at any subsequent one. What the evidence does not give us is a reliable duration, a confirmed mechanism, or a technique that prevents it — and pages that supply those anyway are the reason so many patients arrive at their follow-up convinced something went wrong.
The practical work sits in the consultation. Name the likelihood before treating, describe what the typical pattern feels like, be explicit with migraine patients about reporting a first-week worsening, document off-label jaw treatment as off-label, and know the small set of symptoms that mean assessment rather than reassurance. Those are consultation skills as much as injection skills, and they are what separate a confident practice from a defensive one.
IAPAM’s hands-on Botox® training in Scottsdale, Arizona covers both: live-model injection technique with board-certified physician instructors, alongside the consultation, consent and complication-management framework that keeps patients calm when a predictable side effect shows up. Twenty years of training physicians, nurse practitioners, PAs and dentists sits behind the curriculum.
BOTOX® Cosmetic (onabotulinumtoxinA) US Prescribing Information, revised October 2024. Tables 5–7, Adverse Reactions.
BOTOX® (onabotulinumtoxinA) therapeutic US Prescribing Information, revised November 2023. Chronic Migraine adverse reactions and Warnings.
Dysport®, Xeomin®, Jeuveau®, Daxxify® and Letybo® US Prescribing Information, current revisions as dated in the table above.
Akpınar Ü, Vural O, Civas E, Koycu A. Post-Botulinum Headache in Cosmetic Practice: A Prospective Study. Journal of Cosmetic Dermatology. 2026;25(2).
Bilgin Ş, Ozdemir K, Yaka EC, et al. Evaluating Headache Incidence and Characteristics After Botulinum Toxin Treatment in Blepharospasm and Hemifacial Spasm Patients. Clinical Neuropharmacology. 2024;47(5):157–162.
Zargaran D, Zoller F, Zargaran A, et al. Complications of Cosmetic Botulinum Toxin A Injections to the Upper Face: A Systematic Review and Meta-Analysis. Aesthetic Surgery Journal. 2022;42(5):NP327–NP336.
Allergan Aesthetics. U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence. August 4, 2026.
Disclaimer: This guide is for informational and educational purposes only and does not constitute medical advice. Treatment plans, injection techniques, and dosing must be tailored to each patient by a qualified, licensed provider. Always follow product labeling, your scope of practice, and your state medical and nursing board regulations.
Compare Botox® certification levels — basic, intermediate & advanced training. Learn what each level covers, who it’s for, and how to choose the right program.
Learn Botox® continuing education requirements for physicians, NPs, PAs, and dentists — how many CME/CE credits you need and how to choose quality training.
Master full face Botox injection strategy: unit planning, sequencing, and how to balance the upper, mid, and lower face for natural, harmonious results.
Attend IAPAM’s comprehensive AMA PRA Category 1 CME BOTOX® training weekend and learn the clinical and business foundations for aesthetic practice growth.
✓Hands-on BOTOX® injection training in a clean, multi-million-dollar medspa—not a hotel.
✓Live models and product are provided so you can focus on learning with expert instructors.
✓Build foundations in five non-invasive treatments, with an optional GLP-1 weight-management business add-on.
